Physician profile
Ryne E Hardesty
NPI 1962241190
$2,608.44
in general payments reported to CMS, 2019-2025
10 companies · $2,505 in 2025
The $2,505 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $103 · 2025: $2,505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,210 · Education: $398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,210.46 |
| Education | $397.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $997.67 | 2025 | Carvykti, Rybrevant, Darzalex |
| Genzyme Corporation | $384.15 | 2024-2025 | |
| Abbvie INC. | $353.42 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $247.15 | 2025 | Onivyde, Somatuline Depot |
| Adc Therapeutics America, INC. | $241.54 | 2025 | |
| Syndax Pharmaceuticals, INC. | $121.36 | 2025 | Revuforj |
| Bayer Healthcare Pharmaceuticals INC. | $120.39 | 2025 | |
| Legend Biotech USA INC. | $107.07 | 2025 | Carvykti |
| Genentech USA, INC. | $18.71 | 2025 | Polivy |
| Incyte Corporation | $16.98 | 2025 | Niktimvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryne Hardesty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.